GLP-1 receptor agonist
Liraglutide
Liraglutide after one dose: 50% at ~13 h, 25% at 26 h, 12.5% at 39 h.
Drawn from the half-life in the app's model, ~13 h. The model's figures
- Compound
- Liraglutide
- Symbol
- LIR
- Family
- GLP-1 and incretin
- Parts
- 15
- References
- 13
- Checked
- Last reviewed . Sources are listed below.
Overview
Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist made by Novo Nordisk and sold in the United States as Victoza and Saxenda.1,2 The Victoza label lists two uses: improving glycemic control as an adjunct to diet and exercise in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus, and reducing the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease.1 The Saxenda label lists use in combination with a reduced calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults and pediatric patients aged 12 years and older with body weight greater than 60 kg and obesity, and in adults with overweight in the presence of at least one weight-related comorbid condition.2
The initial approval year printed on both US labels is 2010, and the European Medicines Agency's product information gives 30 June 2009 as the date of first authorisation of Victoza and 23 March 2015 as that of Saxenda.1,2,3,4 The app grades the evidence for liraglutide as strong, and SCALE Obesity and Prediabetes and LEADER, described below, were funded by Novo Nordisk, with the National Institutes of Health as a second funder of LEADER.5,6
How it works
Sources in this part
The Victoza label describes liraglutide as "an acylated human GLP-1 receptor agonist with 97% amino acid sequence homology to endogenous human GLP-1(7-37)".1 It states that liraglutide "increases intracellular cyclic AMP (cAMP) leading to insulin release in the presence of elevated glucose concentrations", "also decreases glucagon secretion in a glucose-dependent manner", and that the mechanism of blood glucose lowering "also involves a delay in gastric emptying".1
The label gives the half-life of native GLP-1(7-37) as 1.5 to 2 minutes because of degradation by dipeptidyl peptidase 4 (DPP-4) and neutral endopeptidases, and says liraglutide "is stable against metabolic degradation by both peptidases and has a plasma half-life of 13 hours after subcutaneous administration".1
Half-life and pharmacokinetics
Values from the Milligram app's model.
- Half-life
- ~13 h
- Bioavailability
- 55%
- Typical dose
- 0.6–3 mg/day
- Route
- SubQ
- Time to peak
- ~8 h
Sources in this part
The figures in the second column of the table are the app's own, shown beside what the sources report.
| Parameter | App's figure | Reported in the sources |
|---|---|---|
| Half-life | About 13 hours | Elimination half-life of approximately 13 hours on the Victoza and Saxenda labels and in the European product information for both, stated after a single subcutaneous dose on the US labels and in the European Victoza text; mean apparent clearance of approximately 1.2 L/h on the Victoza label and 0.9 to 1.4 L/h on the Saxenda label.1,2,3,4 |
| Bioavailability | 55% by subcutaneous injection | Absolute bioavailability of approximately 55% after subcutaneous administration on the Victoza label and in the European product information for Victoza and Saxenda.1,3,4 |
| Time to peak | About 8 hours | Maximum concentrations at 8 to 12 hours post dosing on the Victoza label and in its European product information; at 11 hours post dosing on the Saxenda label and approximately 11 hours in its European product information.1,2,3,4 |
| Duration of action | About 36 hours | The European product information for Victoza states "Liraglutide has 24-hour duration of action"3; the US labels and the European Saxenda text read give no duration of action.1,2,4 |
| Levels | Not held by the app | At 1.8 mg Victoza, an average steady state concentration over 24 hours of approximately 128 ng/mL; with Saxenda 3 mg in people with obesity (BMI 30-40 kg/m2), approximately 116 ng/mL; extensively bound to plasma protein.1,2 |
The chart draws the app's one-compartment model with its half-life of 13 hours and time to peak of 8 hours, an illustration and not a measured level; the labels give maximum concentrations at 8 to 12 hours (Victoza) and 11 hours (Saxenda).1,2
Level over 1 weeks
Level, as a share of the peak after one 1.8 mg dose
As studied: every day (once daily)1.
An illustration from a pharmacokinetic model using a half-life of 13 hours. It is not a measured level or a suggested dose.
What the label pens contain per mL
Sources in this part
The Victoza label lists an injection of 18 mg/3 mL (6 mg/mL) in a prefilled, single-patient-use pen that delivers doses of 0.6 mg, 1.2 mg, or 1.8 mg.1 The Saxenda label lists a 6 mg/mL solution in a 3 mL prefilled, single-patient-use pen that delivers doses of 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg, or 3 mg.2
Strength converter
US label strength (Victoza and Saxenda): 6 mg per mL1
Arithmetic only: the amount is the volume times the strength. The vial's own label states its strength.
Human studies
| Study and year | Design | People | Dose and length | Main result |
|---|---|---|---|---|
| Pi-Sunyer and colleagues, SCALE Obesity and Prediabetes, New England Journal of Medicine 20155 | Double-blind, placebo-controlled; funded by Novo Nordisk7 | 3731 adults without type 2 diabetes, with a BMI of at least 30, or at least 27 with dyslipidemia or hypertension | Liraglutide 3.0 mg (2487) or placebo (1244), once daily subcutaneously, with lifestyle counselling; 56 weeks | Weight loss of 8.4 kg against 2.8 kg (difference -5.6 kg, 95% CI -6.0 to -5.1; last observation carried forward); at least 5% lost by 63.2% against 27.1%; serious events 6.2% against 5.0% |
| Davies and colleagues, SCALE Diabetes, JAMA 20158 | Double-blind, placebo-controlled; sponsored by Novo Nordisk9 | 846 adults with type 2 diabetes and a BMI of 27.0 or greater | Liraglutide 3.0 mg (423), 1.8 mg (211) or placebo (212), once daily subcutaneously; 56 weeks | Weight loss of 6.0% with 3.0 mg, 4.7% with 1.8 mg and 2.0% with placebo (3.0 mg against placebo: -4.00%, 95% CI -5.10% to -2.90%), against -5.9, -4.6 and -2.0 in the registry entry and -5.4% against -1.7% in the Saxenda label's Study 2; more gastrointestinal disorders with 3.0 mg; no pancreatitis reported; discontinuation for adverse events in 39 of 423 on 3.0 mg, 18 of 211 on 1.8 mg and 7 of 212 on placebo; serious adverse events in 37 of 422, 18 of 210 and 13 of 2129 |
| Marso and colleagues, LEADER, New England Journal of Medicine 20166 | Double-blind, placebo-controlled; supported by Novo Nordisk and the National Institutes of Health | 9340 adults with type 2 diabetes and high cardiovascular risk (4668 liraglutide, 4672 placebo) | Liraglutide 1.8 mg (or the maximum tolerated dose) or placebo, once daily subcutaneously; median follow-up 3.8 years | First cardiovascular death, nonfatal myocardial infarction or nonfatal stroke in 608 (13.0%) against 694 (14.9%) (hazard ratio 0.87, 95% CI 0.78 to 0.97); death from any cause in 381 (8.2%) against 447 (9.6%) |
| Buse and colleagues, LEAD-6, Lancet 200910 | Open-label, parallel-group, in 15 countries; funded by Novo Nordisk A/S | Adults with inadequately controlled type 2 diabetes on maximally tolerated metformin, a sulphonylurea, or both | Added liraglutide 1.8 mg once a day (233) or exenatide 10 microg twice a day (231); 26 weeks | HbA1c fell by 1.12% against 0.79% (estimated treatment difference -0.33; 95% CI -0.47 to -0.18); postprandial glucose control was less effective with liraglutide after breakfast and dinner; similar weight losses of 3.24 kg against 2.87 kg; nausea less persistent and minor hypoglycaemia less frequent with liraglutide (25.5% against 33.6%); two patients taking exenatide and a sulphonylurea had a major hypoglycaemic episode |
| Kelly and colleagues, SCALE Teens, New England Journal of Medicine 202011 | Double-blind, placebo-controlled; funded by Novo Nordisk | 251 adolescents aged 12 to under 18 years with obesity and a poor response to lifestyle therapy alone | Liraglutide 3.0 mg or placebo, once daily subcutaneously, with lifestyle therapy; 56 weeks | BMI standard-deviation score difference of -0.22 (95% CI -0.37 to -0.08); gastrointestinal adverse events in 81 of 125 against 46 of 126; discontinuation for adverse events in 13 against 0; serious adverse events in 3 against 5; one suicide on liraglutide, assessed by the investigator as unlikely to be related to the trial treatment; after discontinuation, a greater increase in BMI standard-deviation score with liraglutide (difference 0.15, 95% CI 0.07 to 0.23) |
| Rubino and colleagues, STEP 8, JAMA 202212 | Open-label comparison, 19 US sites; funded by Novo Nordisk A/S | 338 adults with overweight or obesity, without diabetes | Liraglutide 3.0 mg once daily (127) or semaglutide 2.4 mg once weekly (126), or pooled placebo (85); 68 weeks | Weight change of -6.4% with liraglutide against -15.8% with semaglutide (difference -9.4 percentage points, 95% CI -12.0 to -6.8) and -1.9% with pooled placebo; discontinuation for any reason in 27.6% against 13.5%; gastrointestinal adverse events in 82.7% against 84.1% |
The SCALE Obesity and Prediabetes author list includes one author at Novo Nordisk (C.B.J.), the SCALE Diabetes list includes Novo Nordisk A/S, and the SCALE Teens list includes authors at Novo Nordisk (P.A., P.M.H. and N.P.).5,8,11 The records read do not include the authors' limitation statements for these three papers, LEAD-6 and STEP 8, or the disclosure statements for the SCALE papers and LEAD-6. STEP 8 compared two Novo Nordisk products, its authors include three Novo Nordisk employees (Khalid, Sørrig and Wizert), two of whom are also shareholders, a fourth author (Rubino) reports being a Novo Nordisk shareholder, other authors report Novo Nordisk grants or advisory fees (one, Greenway, served on its advisory board for the development of liraglutide), and the report states that sponsor representatives "were involved in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, and approval of the manuscript".12
Deeper analysis: SCALE Obesity and Prediabetes
Pi-Sunyer and colleagues, whose first author is at Columbia University in New York, reported SCALE Obesity and Prediabetes in the New England Journal of Medicine in 2015, with coprimary end points of weight change and the proportions losing at least 5% and more than 10% of initial body weight.5 At week 56 the mean loss was 8.4 kg on liraglutide and 2.8 kg on placebo, and more than 10% of body weight was lost by 33.1% against 10.6% (P<0.001).5 The Saxenda label reports the same study as Study 1, with a least squares mean weight change of -7.4% against -3% (difference -4.5, 95% CI -5.2 to -3.8).2 The label handles missing week 56 values by multiple imputation, while the paper uses last observation carried forward.2,5 People with abnormal glucose measurements at randomization (2,254 of the 3731) were treated for a total of 160 weeks, and the registry entry, with Novo Nordisk A/S as sponsor, lists onset of type 2 diabetes at 160 weeks in 26 of the 1505 people who started the extension on liraglutide against 46 of 749 on placebo, with 1528 and 757 people in its pre-diabetes arms at the start.2,7 The label gives study drug discontinuation of 27% on Saxenda against 35% on placebo in the 56-week trials and 47% against 55% in the 160-week trial.2 In the 56-week trials about 10% on Saxenda and 4% on placebo stopped because of an adverse reaction, and 13% against 6% in the 160-week trial.2 The paper's summary calls the most frequent adverse events "mild or moderate nausea and diarrhea", the funder is listed as Novo Nordisk, and neither the PubMed record nor the registry entry gives a count of deaths.5,7
Deeper analysis: LEADER
Marso and colleagues, from the University of Texas Southwestern Medical Center in Dallas, reported LEADER for the LEADER Steering Committee in the New England Journal of Medicine in 2016.6 The trial was overseen by a steering committee of "11 academic investigators and 4 employees of the sponsor", and the data were analyzed by Statogen Consulting and the sponsor.6
Cardiovascular death occurred in 219 (4.7%) against 278 (6.0%) (hazard ratio 0.78, 95% CI 0.66 to 0.93; P=0.007).6 Nonfatal myocardial infarction and nonfatal stroke were lower with liraglutide "although the differences were not significant", and exploratory outcomes carried no adjustment of P values for multiplicity.6 At 36 months heart rate was 3.0 beats per minute higher with liraglutide.6 Any adverse event occurred in 62.3% against 60.8% and serious adverse events in 49.7% against 50.4%, while adverse events leading to permanent discontinuation occurred in 444 (9.5%) against 339 (7.3%), including nausea in 77 (1.6%) against 18 (0.4%) and serious adverse events in 192 (4.1%) against 245 (5.2%); severe hypoglycemia occurred in 114 against 153 people.6 Acute gallstone disease occurred in 145 (3.1%) against 90 (1.9%) and acute pancreatitis in 18 against 23 people; 13 people on liraglutide and 5 on placebo had pancreatic cancer, and medullary thyroid carcinoma occurred in none against one.6
The authors state that "patients were followed for only 3.5 to 5.0 years", that the benefits and risks "may not apply to patients at lower risk", and that such trials "are not powered to determine the effect of drugs on cancer risk and can therefore neither confirm nor exclude such a possibility".6 Four authors are listed as employees of and stockholders in Novo Nordisk with pending patents related to liraglutide methods, other authors report Novo Nordisk consulting fees, committee fees, grant support or stock, and the editorial support was funded by the sponsor.6
Doses reported in studies and on labels
The app's typical dose of 0.6 to 3 mg a day spans the lowest titration step on both labels and the Saxenda maintenance dosage for adults.1,2
| Source | Setting | Dose reported |
|---|---|---|
| Victoza label1 | Adults with type 2 diabetes | 0.6 mg once daily for one week, then 1.2 mg, then 1.8 mg after one week at 1.2 mg if additional glycemic control is required; the label states the 0.6 mg dosage "is not effective for glycemic control in adults" |
| Victoza label1 | Pediatric patients aged 10 years and older with type 2 diabetes | 0.6 mg once daily for at least one week, then 1.2 mg if additional glycemic control is required, and 1.8 mg if still required, after at least one week at 1.2 mg |
| Saxenda label2 | Adults, weight management | 0.6, 1.2, 1.8 and 2.4 mg daily in weeks 1 to 4, then 3 mg daily from week 5; the label says to consider delaying escalation for approximately one additional week if an increased dose is not tolerated |
| Saxenda label2 | Pediatric patients aged 12 years and older, weight management | 3 mg daily, or 2.4 mg if 3 mg is not tolerated; escalation may take up to 8 weeks, and the dose may be lowered to the previous level if an increase is not tolerated |
| SCALE Obesity and Prediabetes5 | Adults without type 2 diabetes | 3.0 mg once daily; 56 weeks |
| SCALE Diabetes8 | Adults with type 2 diabetes | 3.0 mg or 1.8 mg once daily; 56 weeks |
| LEADER6 | Adults with type 2 diabetes and high cardiovascular risk | 1.8 mg or the maximum tolerated dose once daily; median daily dose 1.78 mg, including periods during which the patients did not receive liraglutide; median follow-up 3.8 years and median time of exposure 3.5 years |
| LEAD-610 | Adults with type 2 diabetes on metformin, a sulphonylurea, or both | 1.8 mg once a day; 26 weeks |
| SCALE Teens11 | Adolescents aged 12 to under 18 years with obesity | 3.0 mg once daily; 56 weeks; the Saxenda label says 82.4% reached 3 mg and 8.8% had 2.4 mg as the maximum tolerated dose2 |
Side effects reported
Sources in this part
The Victoza label's table covers five placebo-controlled glycemic control trials in adults with type 2 diabetes (placebo 661 people, liraglutide 1.2 mg 645, liraglutide 1.8 mg 1024) and lists reactions, excluding hypoglycemia, in at least 5% of Victoza-treated patients and more common than on placebo.1 The Saxenda label's table covers five double-blind, placebo-controlled trials of overweight or obese adults (placebo 1941 people, Saxenda 3384, treated for up to 56 weeks in three trials, 52 weeks in one and 32 weeks in one, with a 160-week subset in one of the 56-week trials) and lists reactions in at least 2% of Saxenda-treated patients and more frequent than on placebo.2 Both labels say adverse reaction rates from one drug's trials cannot be directly compared with rates from another drug's trials.1,2
| Selected reaction | Victoza label: placebo, 1.2 mg, 1.8 mg | Saxenda label: placebo, 3 mg |
|---|---|---|
| Nausea | 5%, 18%, 20% | 13.8%, 39.3% |
| Diarrhea | 4%, 10%, 12% | 9.9%, 20.9% |
| Vomiting | 2%, 6%, 9% | 3.9%, 15.7% |
| Constipation | 1%, 5%, 5% | 8.5%, 19.4% |
| Dyspepsia | 1%, 4%, 7% | 2.7%, 9.6% |
| Headache | 7%, 11%, 10% | 12.6%, 13.6% |
In the Victoza trials, withdrawals due to gastrointestinal adverse reactions occurred in 4.3% of Victoza-treated patients and 0.5% of placebo-treated patients, and severe gastrointestinal adverse reactions in 4.4% (1.2 mg) and 4.2% (1.8 mg) against 1.1%.1 In the Saxenda trials, 9.8% of Saxenda-treated and 4.3% of placebo-treated adults stopped treatment early because of adverse reactions, most often nausea (2.9% against 0.2%), vomiting (1.7% against less than 0.1%) and diarrhea (1.4% against 0%).2
Deeper analysis: the Victoza and Saxenda label warnings
Both labels carry a boxed warning that liraglutide "causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures in both genders of rats and mice" and that it is unknown whether it causes such tumors, including medullary thyroid carcinoma, in humans.1,2 The Victoza label lists a contraindication in people with a personal or family history of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2, and reports 7 cases of papillary thyroid carcinoma on Victoza against 1 on comparators (1.5 against 0.5 cases per 1,000 patient-years) in adult glycemic control trials, most of them under 1 cm in greatest diameter and diagnosed after thyroidectomy prompted by protocol-specified calcitonin or ultrasound screening.1 The Victoza label also describes acute pancreatitis, "including fatal and non-fatal hemorrhagic or necrotizing pancreatitis", observed with GLP-1 receptor agonists including liraglutide, and reports 13 cases of pancreatitis on Victoza against 1 on glimepiride (2.7 against 0.5 cases per 1,000 patient-years), one with necrosis that led to death, though clinical causality could not be established.1 The Saxenda label reports acute pancreatitis confirmed by adjudication in 9 (0.3%) of 3,291 Saxenda-treated patients and 2 (0.1%) of 1,843 placebo-treated patients.2 Acute gallbladder disease is described as 3.1% on Victoza against 1.9% on placebo in LEADER, and in the Saxenda trials as cholelithiasis in 2.2% against 0.8% and cholecystitis in 0.8% against 0.4%, with most Saxenda-treated people with these events requiring cholecystectomy, and the Victoza label says most acute cholecystitis events required hospitalization or cholecystectomy.1,2
Bloodwork and markers
Sources in this part
The app lists blood glucose, HbA1c and body weight as the markers for liraglutide. In the trials above, glycated hemoglobin fell by 0.40 percentage points more with liraglutide than placebo at 36 months in LEADER (95% CI -0.45 to -0.34), and by 1.12% against 0.79% with exenatide in LEAD-6.6,10 In LEADER the mean levels of serum amylase and lipase were higher with liraglutide than with placebo, and calcitonin levels were similar in the two groups (data not shown).6 The Saxenda label lists increased lipase in 5.3% against 2.2% on placebo, and calcitonin at least 2 times the upper limit of normal at the end of the trial in 1.2% of Saxenda-treated and 0.6% of placebo-treated patients.2 The Victoza label says adjusted mean serum calcitonin was higher with Victoza than with placebo but not than with active comparator, by approximately 0.1 ng/L or less.1
Regulatory and anti-doping status
Sources in this part
In the United States both labels print an initial approval year of 2010 and carry the boxed warning described above, with Novo Nordisk named on both labels.1,2 The European product information for Victoza covers "adults, adolescents and children aged 10 years and above with insufficiently controlled type 2 diabetes mellitus", and that for Saxenda covers weight management in adults with an initial BMI of at least 30 kg/m2, or at least 27 to under 30 with at least one weight-related comorbidity, in adolescents from the age of 12 years with obesity and body weight above 60 kg, and in children from the age of 6 to under 12 years with obesity (BMI at or above the 95th percentile) and body weight of at least 45 kg.3,4 The World Anti-Doping Agency's 2026 Prohibited List text read does not name liraglutide.13 Its section S0 covers a pharmacological substance "with no current approval by any governmental regulatory health authority for human therapeutic use", and the text read does not state whether any section applies to liraglutide beyond not naming it.13
Storage and handling
Sources in this part
The Victoza label lists storage before first use in a refrigerator between 36ºF and 46ºF (2ºC to 8ºC), not in the freezer, and after first use for 30 days at controlled room temperature (59ºF to 86ºF, 15ºC to 30ºC) or in a refrigerator.1
What is not known
Sources in this part
The Victoza label states that "It is unknown whether VICTOZA causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans, as the human relevance of liraglutide-induced rodent thyroid C-cell tumors has not been determined".1 The label also states that liraglutide "was not studied" in patients with body weight above 160 kg.1 In STEP 8 the semaglutide against liraglutide comparison was open-label, and the placebo groups were pooled.12 The authors' limitation statements for the SCALE, LEAD-6 and STEP 8 papers are not available in the records read.
Frequently asked questions
What is the half-life of liraglutide?
How long does liraglutide take to reach peak levels?
Is liraglutide banned by WADA?
The World Anti-Doping Agency's 2026 Prohibited List text read does not name liraglutide.13
What did the LEADER trial find?
In LEADER, among 9340 adults with type 2 diabetes at high cardiovascular risk, a first cardiovascular death, nonfatal myocardial infarction or nonfatal stroke occurred in 608 of 4668 people (13.0%) on liraglutide and 694 of 4672 (14.9%) on placebo (hazard ratio 0.87, 95% CI 0.78 to 0.97).6 Cardiovascular death occurred in 219 (4.7%) against 278 (6.0%), discontinuation for adverse events in 444 (9.5%) against 339 (7.3%) and acute gallstone disease in 145 (3.1%) against 90 (1.9%); Novo Nordisk and the National Institutes of Health supported the trial.6
How much weight did people lose on liraglutide in the SCALE trials?
In SCALE Obesity and Prediabetes, in adults without type 2 diabetes, people on liraglutide 3.0 mg lost a mean of 8.4 kg and people on placebo 2.8 kg at 56 weeks (difference -5.6 kg; 95% CI -6.0 to -5.1; last-observation-carried-forward imputation).5 In SCALE Diabetes, in adults with type 2 diabetes, weight loss was 6.0% with 3.0 mg and 2.0% with placebo in the paper, -5.9 and -2.0 in the registry entry, and -5.4% against -1.7% in the Saxenda label's Study 2.8,9,2 Serious events were 6.2% against 5.0% in the first trial and 37 of 422 against 13 of 212 in the second, and discontinuation for adverse events was 39 of 423 against 7 of 212 in the second; Novo Nordisk funded the first and sponsored the second.5,9 The first trial's registry entry lists adverse-event withdrawals by subgroup, such as 152 of 1528 against 29 of 757 in its pre-diabetes arms.7
What are the common side effects of liraglutide?
On the Victoza label, nausea was reported by 5% of adults on placebo, 18% on 1.2 mg and 20% on 1.8 mg, and diarrhea by 4%, 10% and 12%.1 On the Saxenda label, nausea was reported by 39.3% of adults on Saxenda and 13.8% on placebo, diarrhea by 20.9% and 9.9%, constipation by 19.4% and 8.5%, and vomiting by 15.7% and 3.9%.2
How does liraglutide compare with semaglutide for weight loss?
In STEP 8, mean weight change at 68 weeks was -6.4% with liraglutide 3.0 mg and -15.8% with semaglutide 2.4 mg (difference -9.4 percentage points; 95% CI -12.0 to -6.8).12 Gastrointestinal adverse events were reported by 82.7% on liraglutide and 84.1% on semaglutide, and discontinuation for any reason by 27.6% and 13.5%.12 The comparison was open-label and funded by Novo Nordisk A/S.12
Guides, tools and comparisons
- Liraglutide dosageA guide that answers a question on this compound.
- Calculator for LiraglutideA calculator set up for this compound.
- Previous in GLP-1 and incretin: ExenatideThe compound before this one in the class.
- Next in GLP-1 and incretin: Oral SemaglutideThe compound after this one in the class.
References
- VICTOZA (liraglutide) injection, for subcutaneous use. Prescribing information. Novo Nordisk, 2025. DailyMed label
- SAXENDA (liraglutide) injection, for subcutaneous use. Prescribing information. Novo Nordisk, 2026. DailyMed label
- Victoza. Summary of product characteristics. European Medicines Agency. EMA product information
- Saxenda. Summary of product characteristics. European Medicines Agency. EMA product information
- Pi-Sunyer X, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med 2015. PMID 26132939
- Marso SP, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2016. PMC4985288
- ClinicalTrials.gov. NCT01272219. Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities. Novo Nordisk A/S. NCT01272219
- Davies MJ, et al. Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial. JAMA 2015. PMID 26284720
- ClinicalTrials.gov. NCT01272232. Effect of Liraglutide on Body Weight in Overweight or Obese Subjects With Type 2 Diabetes. Novo Nordisk A/S. NCT01272232
- Buse JB, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009. PMID 19515413
- Kelly AS, et al. A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity. N Engl J Med 2020. PMID 32233338
- Rubino DM, et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA 2022. PMC8753508
- World Anti-Doping Agency. World Anti-Doping Code International Standard Prohibited List 2026. WADA list 2026